China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List
Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines
The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment
In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
NHSA Quietly Releases Implementation Guides for Establishing Medical Service Pricing Items
Executive Summary
In China, both public and private not-for-profit hospitals are required to adhere to the Medical Service Pricing Catalogs
China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years
Executive Summary
City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
Accessing Innovative Orphan Therapies in China: Local Advancements
These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
China Local Pilots Expedite Access to Innovative Medicine
These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market
Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
